Kirkland, Washington- July 2024- Kestra Medical Technologies announced that Raymond W. Cohen has joined the board of directors as a new independent board director.
Brian Webster, President & CEO of Kestra said, “Ray is one of the most experienced and accomplished leaders in the medical device industry and has a multi-decade successful track record developing and commercializing emerging medical technologies. Mr.Cohen’s extensive experience in the external defibrillation field and commercial growth strategies will be invaluable to the Kestra team. His track record of strategic exits for both public and private companies, including Axonics’ successful IPO and shareholder value creation as a public entity will no doubt accrue to our benefit as we envision the future of Kestra. On behalf of all of the Kestra stakeholders, we are delighted to welcome him on the board of Kestra.”
Raymond W. Cohen said, “Kestra has a world-class wearable defibrillator product and is poised to compete aggressively in this former monopoly market which is estimated to be in the $1B revenue range. I am looking forward to sharing my experience with Kestra and supporting Mr. Webster and team as they strive to reach their goal of market leadership in the WCD arena.”
Also Read: Oxford Biomedica Welcomes Laurence Espinasse as New Non-Executive Director
Furthermore, Kestra Medical Technologies, Inc., recently closed a $196 million funding round to support the expansion of their commercial organization and advance its mission of protecting at-risk patients with its unique wearable cardioverter defibrillator. Andera Partners, Ally Bridge Group, Longitude Capital, and Omega Investments co-led the round. Also participating were new investors T. Rowe Price, Eventide Asset Management, and Gilmartin Capital. Long-term Investors Bain Capital and Endeavour Vision also participated in the round.
